% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Klassen:283139,
author = {Klassen, Paula Cynthia and Alexudis, Christoforos and
Klose, Veronika and de San José, Nerea Gómez and Huss,
André and Bachhuber, Franziska and Soylu, Önder and
Fazeli, Badrieh and Erhart, Deborah and Laible, Mona and
Anderl-Straub, Sarah and Jesse, Sarah and Otto, Markus and
Ludolph, Albert and Tumani, Hayrettin and Halbgebauer,
Steffen},
title = {{I}ncreased transmembrane protein 119 ({TMEM}119) levels in
the cerebrospinal fluid of patients with mild cognitive
impairment due to {A}lzheimer's disease suggest early
microglial involvement.},
journal = {Alzheimer's $\&$ dementia / Diagnosis, assessment $\&$
disease monitoring},
volume = {18},
number = {1},
issn = {2352-8729},
address = {Hoboken, NJ},
publisher = {Wiley},
reportid = {DZNE-2026-00035},
pages = {e70240},
year = {2026},
abstract = {We aimed to evaluate the potential of the microglial marker
transmembrane protein 119 (TMEM119) in the cerebrospinal
fluid (CSF) as a (differential) diagnostic biomarker for
neurodegenerative diseases.Following assay validation, we
used enzyme-linked immunosorbent assay to measure CSF
TMEM119 in 174 patients from six diagnostic groups:
Alzheimer's disease (AD, n = 35), amyotrophic lateral
sclerosis (ALS, n = 33), cerebral microangiopathy (CM, n =
25), frontotemporal lobar degeneration (FTLD, n = 28), Lewy
body diseases (n = 21), and non-neurodegenerative controls
(n = 33).CSF TMEM119 levels were elevated in the AD group
compared to the control (p = 0.004), CM (p = 0.005), and
FTLD (p = 0.023) groups. Levels were higher in both mild
cognitive impairment (MCI-AD) and dementia (ADD) subgroups
when compared to controls. For the discrimination of AD from
controls, the area under the curve (AUC) was 0.78.Our
results indicate that CSF TMEM119 may have potential as a
biomarker representing microglial involvement in early and
later stages of AD.Elevated levels of TMEM119 were observed
in the CSF of patients with AD.Increased CSF TMEM119 was
seen in MCI-AD patients compared to controls.Elevated levels
in MCI-AD underscore early microglial involvement in AD.In
the AD group, an association was found between CSF TMEM119
and CSF total tau.CSF TMEM119 may provide valuable
information on neuroinflammation.},
keywords = {Alzheimer's disease (Other) / biomarkers (Other) /
cerebrospinal fluid (Other) / microglia (Other) /
neuroinflammation (Other)},
cin = {Clinical Study Center (Ulm) / AG Zhan},
ddc = {610},
cid = {I:(DE-2719)5000077 / I:(DE-2719)1910005},
pnm = {353 - Clinical and Health Care Research (POF4-353) / 354 -
Disease Prevention and Healthy Aging (POF4-354)},
pid = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-354},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41488805},
pmc = {pmc:PMC12756045},
doi = {10.1002/dad2.70240},
url = {https://pub.dzne.de/record/283139},
}